col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

186 Results       Page 1

Elsevier: International Journal of Antimicrobial Agents
  original article Date Title Authors   All Authors
1 [GO] 2024―Mar―08 Chrysin 7-O-β-D-glucuronide is not a potential inhibitor against SARS-CoV-2 main protease Rui Zhang, Jiahao Zhou, Haohao Yan, Xiaoping Liu, Yunyu Chen
2 [GO] 2024―Feb―24 Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018-2021) Emanuele Amodio, Stefano Pizzo, Giuseppe Vella, Valerio De Francisci, Salvatore Antonino Distefano, Eliana Giambelluca, et al. (+6)
3 [GO] 2024―Feb―12 Effectiveness of oseltamivir in reducing COVID-19 related in-hospital deaths: a pharmacoepidemiologic study Char Leung, Li Su, Lucy Taylor, Eduardo Araújo Oliveira, Ana Cristina Simões e Silva
4 [GO] 2024―Jan―23 Effectiveness of mRNA BNT162b2 and inactivated CoronaVac vaccines against severe COVID-19 outcomes among non-hospitalized children aged 1-3 years with SARS-CoV-2 Omicron infection Carlos K.H. WONG, Kristy T.K. LAU, Ivan C.H. AU, Eric H.Y. LAU, Benjamin J. COWLING
5 [GO] 2024―Jan―21 Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy versus monotherapy for high-risk immunocompromised patients with mild to moderate SARS-CoV2 infection during Omicron era. A prospective cohort study J. Calderón-Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca, Maria Luisa Martín Jimenez, Helena de la Torre, María Ródenas-Baquero, et al. (+6)
6 [GO] 2024―Jan―19 Association between high dose of molnupiravir and COVID-19 mortality rate Li-Chen Chang, I-Wen Chen, Kuo-Chuan Hung
7 [GO] 2024―Jan―18 In reply to comment on “Association between high dose of molnupiravir and COVID-19 mortality rate” Zhaoyan Chen, Fangyuan Tian
8 [GO] 2024―Jan―18 Small-molecule antivirals treatment for COVID-19: A systematic review and network meta-analysis Bei Zheng, Qinqin Zhao, Wenjuan Yang, Pinpin Feng, Chuanwei Xin, Yin Ying, et al. (+5)
9 [GO] 2023―Dec―31 Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice Kwang-Soo Shin, Byung-Seok Kim, Soojeong Chang, In Kyung Jung, Hyemin Park, Seowoo Park, et al. (+8)
10 [GO] 2023―Dec―14 Comment on ‘Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19 Ying-Li Lin, Chao-Hung Yu, James Cheng-Chung Wei
11 [GO] 2023―Nov―18 Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19 Yang Yi, Rong Yu, Heng Xue, Zhengtong Jin, Meng Zhang, Yang-oujie Bao, et al. (+4)
12 [GO] 2023―Oct―28 Impact of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia Yong-Cheng Yii, Hong-Mo Shih, Chieh-Lung Chen, Zi-Lun Lai, Yu-Lung Hsu, Chia-Hong Lai, et al. (+2)
13 [GO] 2023―Sep―27 The association between nirmatrelvir plus ritonavir and the outcomes of nonhospitalized obese patients with COVID-19 Jheng-Yan Wu, Mei-Yuan Liu, Ting-Hui Liu, Min-Hsiang Chuang, Wan-Hsuan Hsu, Po-Yu Huang, et al. (+2)
15 [GO] 2023―Aug―06 SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine Chang-sheng Xia, Minghua Zhan, Yudong Liu, Zhi-hong Yue, Ying Song, Feifei Zhang, Hui Wang
16 [GO] 2023―Jul―11 Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19 Mary E. Palmer, Rachel M. Belcher, Anastasia Engeleit, Eric Wenzler, Zackery P. Bulman, Scott T. Benken
17 [GO] 2023―Jul―08 Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicenter randomized controlled clinical trial Shu Okugawa, Mahoko Ikeda, Kosuke Kashiwabara, Takashi Moritoyo, Takao Kohsaka, Toshio Shimizu, et al. (+16)
18 [GO] 2023―Jun―18 Exploration of the optimal GS-441524 trough concentration for treating COVID-19 Yuki Nakano, Yoko Inokuchi, Tadashi Hayama, Toshinori Hirai, Mamoru Nishiyama, Yoshiko Sueyasu, Kenjo Yokoo
19 [GO] 2023―Jun―18 Effective inhibition of HCoV-OC43 and SARS-CoV-2 by phytochemicals in vitro and in vivo. Durbadal Ojha, Forrest Jessop, Catharine M. Bosio, Karin E Peterson
20 [GO] 2023―May―26 Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials Fangyuan Tian, Qiyi Feng, Zhaoyan Chen
21 [GO] 2023―May―13 The battle against fungi- lessons in antifungal stewardship from COVID-19 times: a consensus statement on behalf of the International Society of Antimicrobial Chemotherapy, Alliance for the Prudent Use of Antibiotics, European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial Stewardship, and European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group Souha S. Kanj, Sara F. Haddad, Jacques F. Meis, Paul E. Verweij, Andreas Voss, Riina Rautemaa-Richardson, et al. (+6)
22 [GO] 2023―Apr―30 Clinical effectiveness of molnupiravir in COVID-19 patients undergoing hemodialysis Yi-Chin Chang, Yi-Chun Chen, Chiang-Chi Huang, Chung-Ming Fu, Yueh-Ting Lee, Po-Jung Wu, et al. (+4)
23 [GO] 2023―Apr―22 Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in COVID-19 patients Alessandro Russo, Andrea Bruni, Sara Gullì, Cristian Borrazzo, Angela Quirino, Rosaria Lionello, et al. (+9)
24 [GO] 2023―Jan―02 NIRMATRELVIR AND COVID-19DEVELOPMENT, PHARMACOKINETICS, CLINICAL EFFICACY, RESISTANCE, RELAPSES, AND PHARMACOECONOMICS. Daniele Focosi, Scott McConnell, Shmuel Shoham, Arturo Casadevall, Fabrizio Maggi, Guido Antonellli
25 [GO] 2022―May―17 Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics Rajat Desikan, Pranesh Padmanabhan, Andrzej M. Kierzek, Piet H. van der Graaf
26 [GO] 2022―Feb―06 The effect of sofosbuvir-based treatment on the clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials Chi-Kuei Hsu, Ching-Yi Chen, Wang-Chun Chen, Chih-Cheng Lai, Shun-Hsing Hung, Wei-Ting Lin
27 [GO] 2022―Jan―31 Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2 Laura N Jeffreys, Shaun H Pennington, Jack Duggan, Claire H Caygill, Rose C Lopeman, Alastair F Breen, et al. (+11)
28 [GO] 2022―Jan―06 High dose ivermectin for the early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof of concept clinical trial Dora Buonfrate, Fabio Chesini, Davide Martini, Maria Carla Roncaglioni, Maria Luisa Ojeda Fernandez, Maria Francesca Alvisi, et al. (+12)
29 [GO] 2021―Dec―17 Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice Elishiba Muturi, Wei Hong, Junhua Li, Wan Yang, Jin He, Hongping Wei, Hang Yang
30 [GO] 2021―Oct―25 Evaluation of early antibiotic use in non-severe COVID-19 patients without bacterial infection Xiaoxv Yin, Xing Xu, Hui Li, Nan Jiang, Jing Wang, Zuxun Lu, et al. (+2)
31 [GO] 2021―Oct―14 Change in Antimicrobial Use during COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study Hana R. Winders, Pamela Bailey, Joseph Kohn, Carmen M. Faulkner-Fennell, Sara Utley, Evan Lantz, et al. (+6)
32 [GO] 2021―Sep―23 Assessment of the knowledge and applications of infection control in Ayurvedic health care staff working in COVID-19 intermediate centres, Sri Lanka D. Wickramasinghe, PW Vidanage, DK Lokuhewagama, SAPDC Saranasinghe, SPKH Arachchige, BS Pathum
33 [GO] 2021―Sep―23 Identification of daclatasvir as a repurposed drug against Nsp15 of SASR-CoV2 (COVID-19) by using in silico approaches Prakash Jha, Madhu Chopra
34 [GO] 2021―Sep―23 COVID-19 associated mucormycois - unprecedented experience from a developing country V. Shwetha, C. Sneha, R. Ambica, S. Deepa, A. Aashish, P. Harshita, et al. (+7)
35 [GO] 2021―Sep―23 The relationship between SARS-CoV-2 antibody titers and the severity of COVID-19 Joung Ha Park, Min Jae Cha, Hyewon Choi, Min-Chul Kim, Jin-Won Chung, Kyu-Sun Lee, et al. (+3)
36 [GO] 2021―Sep―23 Vaccine-associated disease enhancement: a case report of post-vaccination COVID-19 Rahajeng N. Tunjungputri, Erpryta Nurdia Tetrasiwi, Merlinda Veronica, Jacub Pandelaki, Fera Ibrahim, Erni Juwita Nelwan
37 [GO] 2021―Sep―23 Impact of COVID-19 pandemic on HIV care delivery and access in Asia Chien-Ching Hung, TinHung Wong, Shikha Singh, Yeni Kim, Jun Yong Choi
38 [GO] 2021―Sep―23 Therapeutics for COVID-19 Yaseen M. Arabi
39 [GO] 2021―Sep―23 Long-term sequelae of COVID-19 Bin Cao
40 [GO] 2021―Sep―23 Secondary bacterial and fungal infections in COVID-19 patients Krithika Varshini M., Vithiya Ganesan, Jhansi Charles
41 [GO] 2021―Sep―23 Psychological effects of paramedics by experience of managing COVID-19 patients Bongyoung Kim, Soyoon Hwang, Hyun Wook Ryoo, Un Sun Chung, So Hee Lee, Ju-Yeon Lee, et al. (+3)
42 [GO] 2021―Sep―23 The estimation of direct hospital costs and Intensive Care Units (ICU) admissions for COVID-19 patients and the assessment of the impact of remdesivir administration in the Saudi Arabian context Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Basem Alraddadi, Alaa Alali, Sam Kozma, et al. (+2)
43 [GO] 2021―Sep―23 Use of personal protective equipment by healthcare workers exposed to COVID-19 patients at a tertiary care hospital in a lower middle-income country T.P.W. Perera, D.M. Mendis, S.S. Manoj, G.K. Iresha, P.C.L.S. Buddhadasa, H.C.L. Hansani, Kushlani Jayatilleke
44 [GO] 2021―Sep―23 Community acquired co-infection and trends in antimicrobial use among COVID-19 patients in a referral center in the Philippines Cybele Lara R. Abad, Joanne Carmela M. Sandejas, Jonnel B. Poblete, Anna Flor G. Malundo, Maria Sonia S. Salamat, Marissa M. Alejandria
45 [GO] 2021―Sep―23 Bacterial and fungal secondary infections in COVID-19 patients in a tertiary healthcare center in Malaysia Siti Roszilawati Ramli, Fashihah Sherina Abdul Hadi, Insyirah Husna Kamaradin, Norazah Ahmad
46 [GO] 2021―Sep―23 Hospitalization decision model for COVID-19 patients with comorbidities Irina Lizinfeld
47 [GO] 2021―Sep―23 Place of COVID-19 transmission in blood transmission: A case report Champika Gamlath, Darshana Wickramasinghe, Eshan Madusha
48 [GO] 2021―Sep―23 Low uptake of seasonal influenza and COVID-19 vaccine in nurses in Hong Kong C.P. Chan, N.S. Wong, S.S. Lee
49 [GO] 2021―Sep―23 Parenteral and oral anticoagulant treatment for hospitalized and post-discharge patients with COVID-19: A systematic review Rahajeng N. Tunjungputri, Erpryta N. Tetrasiwi, Tasykuru Rizqa, Nadia A. Mulansari, Kuntjoro Harimurti
50 [GO] 2021―Sep―23 Real-time PCR detects 4 rapid transmission variants of SARS-CoV-2 Van H. Pham, Chien D. Vo, Ha M. Nguyen, Binh T. Pham, Sa H. Le, Duy K. Trãn, et al. (+5)
51 [GO] 2021―Sep―23 Human airway epithelial Calu-3 cells as the potential platform to study the pathophysiology of SARS-CoV-2 isolated in Malaysia Siti Nur Zawani Rosli, Sitti Rahmawati Dimeng, Farah Shamsuddin, Mohammad Ridhuan Mohd Ali, Nur Afrina Muhamad Hendri, Hana Farizah Zamri, et al. (+5)
52 [GO] 2021―Sep―23 Clinical and laboratory factors in predicting mortality among SARS-CoV-2 RNA positive patients from a tertiary care center in South Tamilnadu - A retrospective observational study Vithiya Ganesan, Raja Sundaramurthy, B Surya Kumar, T Rajendran, Jhansi Charles
53 [GO] 2021―Sep―23 Assessing risk factors for health care associated transmission of SARS-Cov-2 virus infection among health care personnel in a tertiary care hospital, Sri Lanka; a case-control study D.M. Mendis, T.P.W. Perera, S.S. Manoj, G.K. Iresha, P.C.L.S. Buddhadasa, H.C.L. Hansani, Kushlani Jayatilleke
54 [GO] 2021―Sep―23 Effect of Lonicera caerulea on cytokine production of alveolar macrophages by stimulation with SARS-CoV-2-related proteins Masaaki Minami, Mineo Nakamura
55 [GO] 2021―Sep―23 Host-pathogen interactional proteomic atlas of pandemic influenza A virus infection in primary human T cells Jiapei Yu, Hui Li, Bin Cao
56 [GO] 2021―Sep―23 Effect of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine Jinyoung Yang, Jae-Hoon Ko, Jin Yang Baek, Jinyeong Hong, Soyoung Ha, Beomki Lee, et al. (+7)
57 [GO] 2021―Sep―23 Antimicrobial stewardship during the COVID-19 pandemic Timothy M. Rawson
58 [GO] 2021―Sep―23 What we learned from COVID-19 vaccination Eui-Cheol Shin
59 [GO] 2021―Sep―23 Public health response to COVID-19: Global perspective Maria Van Kerkhove
60 [GO] 2021―Sep―23 COVID-19: Lessons from the Unfolding Pandemic Michael T. Osterholm
61 [GO] 2021―Sep―23 Public health response to COVID-19: National perspective from Taiwan Hsien-Ho Lin
62 [GO] 2021―Sep―23 Public health response to COVID-19: Regional perspective Sharon Salmon
63 [GO] 2021―Sep―23 Infection control for COVID-19: Theory and practice Kalisvar Marimuthu
64 [GO] 2021―Sep―23 Indoor transmission of SARS-CoV-2 Hua Qian
65 [GO] 2021―Sep―23 Vaccines against SARS-COV-2 Jerome H. Kim
66 [GO] 2021―Aug―25 Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance Cristhieni Rodrigues, Rodrigo S Freitas-Santos, José Eduardo Levi, Andreza A Senerchia, Ana Tarina A Lopes, Sergio R Santos, et al. (+2)
67 [GO] 2021―Apr―07 Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomized control clinical trial Fahad Faqihi, Abdulrahman Alharthy, Salman Abdulaziz, Abdullah Balhamar, Awad Alomari, Zohair AlAseri, et al. (+6)
68 [GO] 2021―Mar―20 Increased antimicrobial resistance during the COVID-19 pandemic Chih-Cheng Lai, Shey-Ying Chen, Wen-Chien Ko, Po-Ren Hsueh
69 [GO] 2021―Mar―18 Timing and dosage may be the key in the realization of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients Dr Alexis LACOUT, Dr VALERE LOUNNAS, Pr Christian PERRONNE
70 [GO] 2021―Mar―12 Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment Hervé Seligmann
71 [GO] 2021―Feb―16 Effect of hydroxychloroquine and azythromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann Philippe Gautret, Van Thuan Hoang, Philippe Colson, Didier Raoult
72 [GO] 2021―Jan―27 Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals R.J. Brüggemann, D.J.A.R. Moes, K.P. van Rhee, N.E. van 't Veer, B.C.P. Koch, M. van Rossum, et al. (+16)
73 [GO] 2021―Jan―19 Azithromycin, treatment in COVID-19 Omar Belfaqeeh, Jigar Patel, Rajesh Naidu Janapala, Abdulla Alhashmi, Ali Pourmand
74 [GO] 2021―Jan―19 Reply to the letter to the editor “Azithromycin, treatment in COVID-19 Navid Manafi, Fereshteh Ghiasvand
75 [GO] 2021―Jan―04 Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19 Philippe Gautret, Jean-Christophe Lagier, Stéphane Honoré, Van Thuan Hoang, Didier Raoult
76 [GO] 2021―Jan―04 Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19 Philippe Colson, Bernard La Scola, Jean-Christophe Lagier, Philippe Gautret, Didier Raoult
77 [GO] 2021―Jan―04 Advanced statistical methods and designs for clinical trials for COVID-19 Guogen Shan, Weizhen Wang
78 [GO] 2021―Jan―04 Response to advances statistical methods and designs for clinical trials for COVID-19 Philippe Gautret, Van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult
79 [GO] 2021―Jan―04 Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature Jason D. Goldman, George Diaz, Walter J. Urba
80 [GO] 2021―Jan―04 Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature. Philippe Gautret, Van Thuan Hoang, Stéphane Honoré, Yanis Roussel, Matthieu Million, Jean-Christophe Lagier, Didier Raoult
81 [GO] 2021―Jan―04 Can we use hydroxychloroquine to treat COVID-19 now? Jun Chen, Danping Liu, Lin Yin, Lijun Zhang, Hongzhou Lu
82 [GO] 2021―Jan―04 Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients Philippe Gautret, Stéphane Honoré, Jean-Christophe Lagier, Didier Raoult
83 [GO] 2021―Jan―04 Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. Matthieu Million, Yanis Roussel, Philippe Gautret, Didier Raoult
84 [GO] 2021―Jan―04 Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial. Philippe Gautret, Van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult
85 [GO] 2021―Jan―04 Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial Luis Gabriel Parra-Lara, Juan José Martinez-Arboleda, Daniel Francisco Isaza-Pierotti, Fernando Rosso
86 [GO] 2021―Jan―04 Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial Marcelo Rodrigues dos Santos
87 [GO] 2021―Jan―04 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited Philippe Gautret, Jean-Christophe Lagier, Stéphane Honoré, Van Thuan Hoang, Philippe Colson, Didier Raoult
88 [GO] 2021―Jan―04 Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes Philippe Gautret, Van Thuan Hoang, Jean-Christophe Lagier, Didier Raoult
89 [GO] 2021―Jan―04 Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” Carlos Gustavo Wambier
90 [GO] 2021―Jan―04 Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” Mohamed O Saad
91 [GO] 2021―Jan―04 Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load Tuan V. Nguyen
92 [GO] 2021―Jan―04 Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load. Philippe Gautret, Van Thuan Hoang, Hervé Chaudet, Jean-Christophe Lagier, Didier Raoult
93 [GO] 2021―Jan―02 Passive immunization and its rebirth in the era of the COVID-19 pandemic Charles S. Pavia, Gary P. Wormser
94 [GO] 2020―Dec―30 Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine Marion Plaze, David Attali, Matthieu Prot, Anne-Cécile Petit, Michael Blatzer, Fabien Vinckier, et al. (+8)
95 [GO] 2020―Dec―25 Plasma exchange in the treatment of complex COVID-19 related critical illness: controversies and perspectives Ziad A. Memish, Fahad Faqihi, Abdulrahman Alharthy, Saleh A Alqahtani, Dimitrios Karakitsos
96 [GO] 2020―Dec―23 Different mutations in SARS-CoV-2 associate with severe and mild outcome Ádám Nagy, Sándor Pongor, Balázs Győrffy
97 [GO] 2020―Dec―17 Early Clinical Outcomes with Tocilizumab for Severe Covid-19: A Two-Center Retrospective Study Steven M. Smoke, Karan Raja, Patrick Hilden, Nicole M. Daniel
98 [GO] 2020―Dec―13 Reply to the letter to the editor “Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.” Nicolas Dauby, Lucy Catteau, Joris Hautekiet, Marion Montourcy, Emmanuel Bottieau, Els Goetghebeur, Dominique Van Beckhoven
99 [GO] 2020―Dec―09 Vertical transmission and kidney damage in newborns from coronavirus disease 2019 infection pregnant mother Zheng He, Yinian Fang, Qin Zuo, Xiaoxing Huang, Yongfang Lei, Xiuhua Ren, Dong Liu
100 [GO] 2020―Nov―28 Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19 S. RUIZ, D. CONCORDET, T. LANOT, B. GEORGES, P. GOUDY, S. BAKLOUTI, et al. (+8)
101 [GO] 2020―Nov―28 COVID-19 in hospitalized patients in Spain: a cohort study in Madrid Carmen Rodriguez-Gonzalez, Esther Chamorro-de-Vega, Maricela Valerio, Miguel Angel Amor-Garcia, Francisco Tejerina, Milagros Sancho-Gonzalez, et al. (+14)
102 [GO] 2020―Nov―28 A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin Martin D. Hellwig, Anabela Maia
103 [GO] 2020―Nov―28 Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality Nicolas De Schryver, Nicolas Serck, Marco Vinetti, Ludovic Gérard
104 [GO] 2020―Nov―27 Klebsiella pneumoniae infections in COVID-19 patients: a two-month retrospective analysis in an Italian hospital Gabriele Arcari, Giammarco Raponi, Federica Sacco, Giulia Bibbolino, Federica Maria Di Lella, Francesco Alessandri, et al. (+6)
105 [GO] 2020―Nov―13 Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020 Tran Duc Anh Ly, Didier Zanini, Vincent Laforge, Sylvie Arlotto, Stephanie Gentile, Helene Mendizabal, et al. (+15)
106 [GO] 2020―Nov―12 Randomized Controlled Trials for COVID-19: Evaluation of Optimal Randomization Methodologies - Need for the Data Validation of the Completed Trials, and to Improve the Ongoing and Future Randomized Trial Designs Venkata R. Emani, Sanjeev Goswami, Dheeraj Nandanoor, Shaila R. Emani, Nidhi K. Reddy, Raghunath Reddy
107 [GO] 2020―Nov―06 LPD-12, a Promising Lipopeptide to Control COVID-19 Trinath Chowdhury, Piyush Baindara, Santi M. Mandal
108 [GO] 2020―Nov―06 Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study Dr. Deba Prasad Dhibar, Dr. Navneet Arora, Dr. Arpit Kakkar, Dr. Neeraj Singla, Dr. Ritin Mohindra, Dr. Vikas Suri, et al. (+6)
109 [GO] 2020―Nov―02 Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial Guoming Li, Mei Yuan, Haihong Li, Changsheng Deng, Qi Wang, Yexiao Tang, et al. (+10)
110 [GO] 2020―Oct―26 COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study Roland Derwand, Martin Scholz, Vladimir Zelenko
111 [GO] 2020―Oct―24 Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: a Meta-analysis Teodoro J. Oscanoa, Xavier Vidal, Jørgen K. Kanters, Roman Romero-Ortuno
112 [GO] 2020―Oct―23 Therapeutic Modalities and Novel Approaches in Regenerative Medicine for COVID-19 Roya Ramezankhani, Roya Solhi, Arash Memarnejadian, Fatemeharefeh Nami, Seyed MohammadReza Hashemian, Tine Tricot, et al. (+2)
113 [GO] 2020―Oct―16 Methylene blue inhibits the replication of SARS-Cov-2 in vitro Mathieu Gendrot, Julien Andreani, Isabelle Duflot, Manon Boxberger, Marion Le Bideau, Joel Mosnier, et al. (+7)
114 [GO] 2020―Oct―09 Projected supportive effects of Pycnogenol® in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection Franziska Weichmann, Peter Rohdewald
115 [GO] 2020―Sep―25 Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients Priya Nori, Wendy Szymczak, Yoram Puius, Anjali Sharma, Kelsie Cowman, Philip Gialanella, et al. (+7)
116 [GO] 2020―Sep―25 Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics Arafat Rahman Oany, Mamun Mia, Tahmina Pervin, Md. Junaid, S.M. Zahid Hosen, Mohammad Ali Moni
117 [GO] 2020―Aug―27 Antimicrobial stewardship program, a vital resource for hospitals during the global outbreak of Coronavirus Disease 2019 (COVID-19) Yixin Liew, Winnie Hui Ling Lee, Lunyi Tan, Andrea Lay Hoon Kwa, Siew Yee Thien, Benjamin Pei Zhi Cherng, Shimin Jasmine Chung
118 [GO] 2020―Aug―25 NSafety and Effectiveness of Azithromycin in Patients with COVID-19: an open-label randomized trial Ehsan Sekhavati, Fatemeh Jafari, SeyedAhmad SeyedAlinaghi, Saeidreza Jamali Moghadam Siahkali, Sara Sadr, Mohammad Tabarestani, et al. (+12)
119 [GO] 2020―Aug―24 Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19 Sergio Padilla, Guillermo Telenti, Lucía Guillén, José Alberto García, Javier García-Abellán, Carolina Ding, et al. (+4)
120 [GO] 2020―Aug―24 Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants Lucy Catteau, Nicolas Dauby, Marion Montourcy, Emmanuel Bottieau, Joris Hautekiet, Els Goetghebeur, et al. (+5)
121 [GO] 2020―Aug―18 Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948] Lisheng Wang, Yiru Wang, Dawei Ye, Qingquan Liu
122 [GO] 2020―Aug―08 Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results Alexandre Lopez, Gary Duclos, Bruno Pastene, Karine Bezulier, Romain Guilhaumou, Caroline Solas, et al. (+2)
123 [GO] 2020―Aug―02 nImpact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time Benjamin Davido, Ghilas Boussaid, Isabelle Vaugier, Thibaud Lansaman, Frédérique Bouchand, Christine Lawrence, et al. (+8)
124 [GO] 2020―Jul―30 Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19 Emre Kara, Kutay Demirkan, Serhat Unal
125 [GO] 2020―Jul―30 Lactoferrin as potential preventative and treatment for COVID-19 Raymond Chang, Tzi Bun Ng, Wei-Zen Sun
126 [GO] 2020―Jul―30 Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): A link between antiviral and anticancer mechanisms? Daniel F. Alonso, Hernán G. Farina
127 [GO] 2020―Jul―30 In silico Study of Azithromycin, Chloroquine and Hydroxychloroquine and their Potential Mechanisms of Action against SARS-CoV-2 Infection Helyson Lucas Bezerra Braz, João Alison de Moraes Silveira, Aline Diogo Marinho, Maria Elisabete Amaral de Moraes, Manoel Odorico de Moraes Filho, Helena Serra Azul Monteiro, Roberta Jeane Bezerra Jorge
128 [GO] 2020―Jul―23 Diagnostic performance of initial blood urea nitrogen combined with D-Dimer levels for predicting in-hospital mortality in COVID-19 patients Anying Cheng, Liu Hu, Yiru Wang, Luyan Huang, Lingxi Zhao, Congcong Zhang, et al. (+8)
129 [GO] 2020―Jul―23 Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study Tong Song, Su Yuan, Yu Yuan, Wu Chuangyan, Chen Jiuling, Wang Sihua, Jiang Jinjun
130 [GO] 2020―Jul―23 Tocilizumab for severe COVID-19: a systematic review and meta-analysis Shao-Huan Lan, Chih-Cheng Lai, Hui-Ting Huang, Shen-Peng Chang, Li-Chin Lu, Po-Ren Hsueh
131 [GO] 2020―Jul―17 Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal. Mohammad Sultan Khuroo, Ahmad A Sofi, Mohammad Khuroo
132 [GO] 2020―Jul―16 No evidence of SARS-CoV-2 circulation before the identification of the first Swiss SARS-CoV-2 case. Loic Lhopitallier, Thomas Brahier, Onya Opota, Andreas Kronenberg, Yolanda Mueller, Olivier Hügli, et al. (+2)
133 [GO] 2020―Jul―13 Publishing in face of the COVID-19 pandemic Andreas Voss, Geoffrey Coombs, Serhat Unal, Raphael Saginur, Po-Ren Hsueh
134 [GO] 2020―Jul―13 Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949 Frits R. Rosendaal
135 [GO] 2020―Jul―13 Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks? Julian D Machiels, Chantal P Bleeker-Rovers, Rob ter Heine, Janette Rahamat-Langendoen, Quirijn de Mast, Jaap ten Oever, et al. (+3)
136 [GO] 2020―Jul―10 Adaptation of Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses - A reply to Fear versus Data Konstantin S. Sharov
137 [GO] 2020―Jul―04 Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study Firouzé BANI-SADR, Maxime HENTZIEN, Madeline PASCARD, Yohan N'GUYEN, Amélie SERVETTAZ, Laurent ANDREOLETTI, et al. (+2)
138 [GO] 2020―Jul―04 COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus Yang Song, Min Zhang, Ling Yin, Kunkun Wang, Yiyi Zhou, Mi Zhou, Yun Lu
139 [GO] 2020―Jul―04 A pharmacological perspective of Chloroquine in SARS-CoV-2 infection Teodoro J. Oscanoa, Roman Romero-Ortuno, Alfonso Carvajal, Andrea Savarino
140 [GO] 2020―Jul―03 Letter to the Editor Regarding the recent contribution by Roussel et al. (SARS-CoV-2: Fear Versus Data) Axel Mosig
141 [GO] 2020―Jun―13 Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b Sun In Hong, Byung-Han Ryu, Yong Pil Chong, Seungjun Lee, Sunjoo Kim, Ho Cheol Kim, et al. (+3)
142 [GO] 2020―Jun―11 Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors Jun He, Lijun Hu, Xiaojun Huang, Chenran Wang, Zhimin Zhang, Ying Wang, et al. (+2)
143 [GO] 2020―Jun―10 Macrolides and viral infections: focus on azithromycin in COVID-19 pathology Arianna Pani, Marinella Lauriola, Alessandra Romandini, Francesco Scaglione
144 [GO] 2020―Jun―10 Procalcitonin levels in COVID-19 patients Rui Hu, Chaofei Han, Shiyao Pei, Mingzhu Yin, Xiang Chen
145 [GO] 2020―Jun―10 Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies Atul Sharma, Swapnil Tiwari, Manas Kanti Deb, Jean Louis MARTY
146 [GO] 2020―Jun―06 Widely available lysosome targeting agents should be considered as a potential therapy for COVID-19 J. Homolak, I. Kodvanj
147 [GO] 2020―Jun―02 Tocilizumab administration in a refractory case of COVID-19 Farzaneh Dastan, Seyed Alireza Nadji, Ali Saffaei, Payam Tabarsi
148 [GO] 2020―May―23 IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS Giancarlo Ceccarelli, Francesco Alessandri, Gabriella d'Ettorre, Cristian Borrazzo, Ornella Spagnolello, Alessandra Oliva, et al. (+4)
149 [GO] 2020―May―22 Extra-respiratory manifestations of COVID-19 Chih-Cheng Lai, Wen-Chien Ko, Ping-Ing Lee, Shio-Shin Jean, Po-Ren Hsueh
150 [GO] 2020―May―22 Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports Valeria Gaspari, Corrado Zengarini, Sonia Greco, Valeria Vangeli, Antonio Mastroianni
151 [GO] 2020―May―22 A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic Satyajit Tripathy, Barsha Dassarma, Somenath Roy, Hlupheka Chabalala, Motlalepula Gilbert Matsabisa
152 [GO] 2020―May―13 nSynergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal Jacques Fantini, Henri Chahinian, Nouara Yahi
153 [GO] 2020―May―11 Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. Ciccullo A., Borghetti A., Zileri Dal Verme L., Tosoni A., Lombardi F., Garcovich M., et al. (+4)
154 [GO] 2020―May―08 Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking Ran Yu, Liang Chen, Rong Lan, Rong Shen, Peng Li
155 [GO] 2020―May―07 Tocilizumab in COVID-19: beware of risk of intestinal perforation Jens Vikse, Brandon Michael Henry
156 [GO] 2020―May―03 SARS-CoV-2 was already spreading in France in late December 2019 A. Deslandes, V. Berti, Y. Tandjaoui-Lambotte, Chakib Alloui, E. Carbonnelle, J.R. Zahar, et al. (+2)
157 [GO] 2020―Apr―30 May drug-related cardiovascular toxicities persist after hospital discharge in COVID-19 patients? Emre Kara, Ahmet Cagkan Inkaya, Kutay Demirkan
158 [GO] 2020―Apr―29 Global coronavirus disease 2019: what has daily cumulative index taught us? Chih-Cheng Lai, Cheng-Yi Wang, Ya-Hui Wang, Po-Ren Hsueh
159 [GO] 2020―Apr―28 Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein ? Naveen Vankadari
160 [GO] 2020―Apr―24 Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 PanDong LuoLiu, Juan Li
161 [GO] 2020―Apr―17 Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals? Sun Hee Lee, Hyunjin Son, Kyong Ran Peck
162 [GO] 2020―Apr―16 Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies Ming Zhao
163 [GO] 2020―Apr―14 Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection Hua Shi, Chaomin Zhou, Pinghong He, Sheng Huang, Youjun Duan, Xuesheng Wang, et al. (+4)
164 [GO] 2020―Apr―12 Chloroquine as prophylactic agent against COVID-19? Mathieu Gendrot, Emilie Javelle, Erwan Le Dault, Axelle Clerc, Hélène Savini, Bruno Pradines
165 [GO] 2020―Apr―10 Drug repositioning an alternative for the treatment of coronavirus COVID-19 Marissa B. Serafin, Angelita Bottega, Vitória S. Foletto, Taciéli F. da Rosa, Andreas Hörner, Rosmari Hörner
166 [GO] 2020―Apr―10 Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections Hanan Polansky, Gillad Lori
167 [GO] 2020―Apr―04 COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: Prevention and Therapeutic Strategies Jaffar A. Al-Tawfiq, Ziad A. Memish
168 [GO] 2020―Apr―04 Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage Mark Olsen, Sarah Elizabeth Cook, Vanthida Huang, Niels Pedersen, Brian G. Murphy
169 [GO] 2020―Apr―03 Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection Jacques Fantini, Coralie Di Scala, Henri Chahinian, Nouara Yahi
170 [GO] 2020―Mar―29 Coronavirus disease 2019 (COVID-19): current status and future perspective Heng Li, Shang-Ming Liu, Xiao-Hua Yu, Shi-Lin Tang, Chao-Ke Tang
171 [GO] 2020―Mar―29 The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Chi Zhang, Zhao Wu, Jia-Wen Li, Hong Zhao, Gui-Qiang Wang
172 [GO] 2020―Mar―29 Recent Progress in understanding 2019 Novel Coronavirus associated with Human Respiratory Disease: Detection, Mechanism and Treatment Shuntong Kang, Wenyao Peng, Yuhao Zhu, Shiyao Lu, Min Zhou, Wei Lin, et al. (+5)
173 [GO] 2020―Mar―28 The epidemiology, diagnosis and treatment of COVID-19 Pan Zhai, Yanbing Ding, Xia Wu, Junke Long, Yanjun Zhong, Yiming Li
174 [GO] 2020―Mar―28 Complex emergencies of COVID-19: management and experience in Zhuhai Hao Jin, Ligong Lu, Junwei Liu, Min Cui
175 [GO] 2020―Mar―20 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Morgane Mailhe, et al. (+12)
176 [GO] 2020―Mar―19 A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence Li-sheng Wang, Yi-ru Wang, Da-wei Ye, Qing-quan Liu
177 [GO] 2020―Mar―19 Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status Chih-Cheng Lai, Cheng-Yi Wang, Ya-Hui Wang, Shun-Chung Hsueh, Wen-Chien Ko, Po-Ren Hsueh
178 [GO] 2020―Mar―19 SARS-CoV-2: fear versus data Yanis Roussel, Audrey Giraud-Gatineau, Marie-Thérèse Jimeno, Jean-Marc Rolain, Christine Zandotti, Philippe Colson, Didier Raoult
179 [GO] 2020―Mar―17 Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine Zahra Sahraei, Minoosh Shabani, Shervin Shokouhi, Ali Saffaei
180 [GO] 2020―Mar―13 Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Sophie Alexandra Baron, Christian Devaux, Philippe Colson, Didier Raoult, Jean-Marc Rolain
181 [GO] 2020―Mar―12 New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Christian A. Devaux, Jean-Marc Rolain, Philippe Colson, Didier Raoult
182 [GO] 2020―Mar―07 VSI: COVID-19 Therapeutic Didier Raoult, Po-Ren Hsueh, Stefani Stefania, Jean-Marc Rolain
183 [GO] 2020―Mar―06 Arguments in favor of remdesivir for treating SARS-CoV-2 infections Wen-Chien Ko, Jean-Marc Rolain, Nan-Yao Lee, Po-Lin Chen, Ching-Tai Huang, Ping-Ing Lee, Po-Ren Hsueh
184 [GO] 2020―Mar―04 Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Philippe Colson, Jean-Marc Rolain, Jean-Christophe Lagier, Philippe Brouqui, Didier Raoult
185 [GO] 2020―Feb―17 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Chih-Cheng Lai, Tzu-Ping Shih, Wen-Chien Ko, Hung-Jen Tang, Po-Ren Hsueh
186 [GO] 2020―Feb―15 Chloroquine for the 2019 novel coronavirus Philippe Colson, Jean-Marc Rolain, Didier Raoult

186 Results       Page 1


Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.006 sec